SML2260
Taspoglutide trifluoroacetate salt
≥95% (HPLC)
别名:
8-(2-Methylalanine)-35-(2-methylalanine)-36-L-argininamide-7-36-glucagon-like peptide I (human) trifluoroacetate salt, BIM 51077 trifluoroacetate salt, R1583 trifluoroacetate salt, RO 5073031 trifluoroacetate salt, [Aib8,35]hGLP-1(7-36)NH2; H-His-2-methyl-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-2-methyl-Ala-Arg-CONH2 trifluoroacetate salt
登录查看公司和协议定价
所有图片(1)
About This Item
经验公式（希尔记法）:
C152H232N40O45 · xC2HF3O2
CAS号:
分子量:
3339.71 (free base basis)
UNSPSC代码:
51111800
NACRES:
NA.77
推荐产品
方案
≥95% (HPLC)
表单
lyophilized powder
颜色
white to beige
运输
wet ice
储存温度
−20°C
生化/生理作用
Taspoglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist. Taspoglutide improves glucose tolerance, postprandial glucose, body weight, glycaemic control and insulin sensitivity in the Zucker diabetic fatty rat.
long-acting glucagon-like peptide 1 (GLP-1) receptor agonist
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
新产品
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
S R K Seshasai et al.
Diabetes, obesity & metabolism, 17(5), 505-510 (2015-02-07)
To study the short-term cardiovascular effects of the once-weekly glucagon-like peptide-1 receptor agonist taspoglutide. We conducted a meta-analysis of individual-participant data from nine randomized controlled trials in the T-Emerge programme, which assessed the efficacy and safety of taspoglutide in type
K Pabreja et al.
British journal of pharmacology, 171(5), 1114-1128 (2013-07-31)
The incidence of type 2 diabetes in developed countries is increasing yearly with a significant negative impact on patient quality of life and an enormous burden on the healthcare system. Current biguanide and thiazolidinedione treatments for type 2 diabetes have
E Sebokova et al.
Diabetes, obesity & metabolism, 12(8), 674-682 (2010-07-02)
Glucagon-like peptide-1 (GLP-1) receptor agonists are a novel class of pharmacotherapy for type 2 diabetes. We investigated the effects of a novel, long-acting human GLP-1 analogue, taspoglutide, in the Zucker diabetic fatty (ZDF) rat, an animal model of type 2
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门